Trials in women

Area of Science:

• Pharmacology
• Clinical Trials
• Women's Health

Background:

• Historically, women of childbearing age were excluded from clinical trials, often deemed a 'vulnerable population'.
• Recent policy shifts have led to increased female participation in clinical trials.
• This change promotes respect for women's autonomy in healthcare decisions and ensures equitable access to new medications.

Purpose of the Study:

• To advocate for the inclusion of women in clinical trials.
• To emphasize the need for gender-specific analysis of drug efficacy and tolerability, particularly for antiepileptic drugs (AEDs).
• To highlight critical considerations for women across reproductive stages, including pregnant and lactating individuals.

Main Methods:

• Review of historical exclusion and recent policy changes regarding women in clinical trials.
• Discussion of the implications of increased female participation.
• Identification of key areas for future research in sex-specific drug evaluation.

Main Results:

• Increased participation of women in clinical trials respects their decision-making capacity.
• Early evaluation of drugs in the ultimate user population (women) is now possible.
• Equal opportunities for women to benefit from therapeutic advancements are being established.

Conclusions:

• Clinical trials must be designed to identify sex-related effects of drugs, especially antiepileptic drugs (AEDs).
• Research should address menstrual cycle, reproductive stages, hormonal therapy interactions, reproductive function, and prenatal exposure effects.
• Special attention is crucial for pregnant and lactating women, prioritizing offspring safety unless maternal benefits are substantial.